Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

Survival of Stage IIIA NSCLC Patients with Changes in N Stage after Neoadjuvant Chemoradiotherapy

IIIA기 비소세포 폐암환자에서 신보조 항암방사선치료 후 N병기의 변화에 따른 생존률 비교

  • Bae, Chi-Hoon (Department of Thoracic and Cardiovascular Surgery, Daegu Catholic University Medical Center, Catholic University of Daegu School of Medicine) ;
  • Park, Seung-Il (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Yong-Hee (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Dong-Kwan (Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine)
  • 배지훈 (대구가톨릭대학교 의과대학 흉부외과학교실) ;
  • 박승일 (울산대학교 의과대학 서울아산병원 흉부외과학교실) ;
  • 김용희 (울산대학교 의과대학 서울아산병원 흉부외과학교실) ;
  • 김동관 (울산대학교 의과대학 서울아산병원 흉부외과학교실)
  • Published : 2008.10.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Non-small cell lung cancer (NSCLC) patients histologically proven to have stage N2 disease by media-stinoscope or thoracoscope underwent subsequent neoadjuvant chemoradiotherapy. This study was designed to find out if there were any differences in survival or recurrence rates between N2 positive and N2 negative patients. Material and Method: Between January 1998 and December 2005, we retrospectively analyzed 69 patients who were divided into three groups. Group A consisted of patients whose N stage was downstaged, group B of patients whose N stage was the same, and Group C of patients who could not undergo surgery because of disease progression during neoadjuvant chemoradiotherapy. We analyzed and compared the mean survival, three-year survival, mean disease-free survival, and three-year disease-free survival rates for the three groups. Result: There were no demographic differences among the groups. The mean survival was 58, 47, and 21 months for groups A, B, and C, respectively. The mean survival was longest in group A, but no statistically significant difference was found on A-B or B-C group comparison (p>0.05). However, a significant difference was noted between group A and group C (p : 0.01). Three-year survival rates were 67%, 41%, and 21.6% for groups A, B, and C, respectively, with a statistical difference similar to that seen in mean survival. The mean disease-free survival was 44 months in group A and 45 months in group B, with no statistically significant difference noted. No significant differences were noted in the three-year disease-free survival rates (55.1%, 46.8%). Conclusion: There were no significant differences in survival or recurrence rates with changes in N stage after neoadjuvant chemoradiotherapy. However, mean survival, three-year survival, and three-year disease-free survival rates tended to be higher in downstaged patients. Nevertheless, the difference was statistically insignificant, and therefore further studies with more patients and longer follow-up are necessary to clarify the positive effects on the survival and prognosis of downstaged patients.

배경: 본 연구는 술전 종격동 내시경 혹은 흉강경을 통한 종격동 림프절 생검을 통해 병리조직학적으로 N2 진단을 받고 신보조 항암방사선치료를 받은 환자에 있어서 신보조 항암방사선치료 후 N병기의 변화에 따른 생존률 및 재발률에 미치는 영향에 대해 알아보고자 하였다. 대상 및 방법: 1998년 1월에서 2005년 12월 사이에 조직학적 N2로 확진된 환자 69명을 대상으로 후향적 연구를 진행하였다. 이들을 3그룹으로 나누어 신보조 항암방사선치료 후 병기가 낮아진 환자들을 그룹 A, 변화 없는 환자들을 그룹 B, 그리고 신보조 항암방사선 치료중 병기가 악화되어 수술을 진행하지 못한 환자들을 그룹 C로 구분하여 각 그룹간 평균생존기간, 3년 생존률 및 평균무병생존기간, 3년 무병생존률을 조사하였고 이들을 비교 분석해 보았다. 결과: 연령, 성별, 폐암의 조직형 및 수술명은 그룹별 유의한 차이는 없었다. 평균 생존기간은 그룹 A, B, C에서 각각 58, 47, 21개월로 그룹A가 가장 높았으나 A-B 및 B-C 사이에는 통계적으로 유이한 차이는 없었고 그룹 A와 C 사이에만 통계적으로 유의한 차이(p : 0.01)를 보였다. 3년 생존률 역시 그룹 A, B, C에서 67%, 41%, 21.6%로 평균생존기간과 비슷한 차이를 보였다. 평균무병생존기간은 그룹 A, B에서 44, 45개월로 통계적으로 유의한 차이는 보이지 않았고 3년 무병생존률도 55.1%, 46.8%로 통계적으로 유의한 차이는 보이지 않았다. 결론: IIIa기 폐암 환자에서 술전 항암방사선 치료 후 N병기가 감소된 그룹A에서 감소되지 않은 그룹 B보다 Mean survival, 3-Yr survival rate 및 3-Yr disease-free survival rate가 더 높은 경향을 볼 수 있었다. 그러나 통계학적 유의성은 없었으므로 더 명확한 결론을 위해서는 향후 더 많은 case 및 오랜 기간의 추적관찰이 필요할 것으로 생각된다.

Keywords

References

  1. Brunelli A, Xiume' F, Al Refai M, Salati M, Marasco R, Sabbatini A. Gemcitabine-cisplatin chemotherapy before lung resection: a case-matched analysis of early outcome. Ann Thorac Surg 2006;81:1963-8 https://doi.org/10.1016/j.athoracsur.2006.01.012
  2. Perrot E, Guibert B, Mulsant P, et al. Preoperative chemotherapy does not increase complications after nonsmall cell lung cancer resection. Ann Thorac Surg 2005;80:423-7 https://doi.org/10.1016/j.athoracsur.2005.02.043
  3. Martin LW, Correa AM, Hofstetter W, et al. The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution. J Thorac Cardiovasc Surg 2005;130:1601-10 https://doi.org/10.1016/j.jtcvs.2005.08.010
  4. Machtay M, Lee JH, Stevenson JP, et al. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. J Thorac Cardiovasc Surg 2004;127:108-13 https://doi.org/10.1016/j.jtcvs.2003.07.027
  5. Cerfolio RJ, Bryant AS, Spencer SA, Bartolucci AA. Pulmonary resection after high-dose and low-dose chest irradiation. Ann Thorac Surg 2005;80:1224-30 https://doi.org/10.1016/j.athoracsur.2005.02.091
  6. Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000;70:1826-31 https://doi.org/10.1016/S0003-4975(00)01585-X
  7. Granetzny A, Striehn E, Bosse U, et al. A phase II single- institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer. Ann Thorac Surg 2003;75:1107-12 https://doi.org/10.1016/S0003-4975(02)04719-7
  8. Sonett JR, Suntharalingam M, Edelman MJ, et al. Pulmonary resection after curative intent radiotherapy (＞59 gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg 2004;78:1200-5 https://doi.org/10.1016/j.athoracsur.2004.04.085
  9. Takeda S, Maeda H, Okada T, et al. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer. Eur J Cardiothorac Surg 2006;30: 184-9 https://doi.org/10.1016/j.ejcts.2006.03.054
  10. Port JL, Korst RJ, Lee PC, et al. Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg 2005;79:1686-90 https://doi.org/10.1016/j.athoracsur.2004.10.057
  11. De Waele M, Hendriks J, Lauwers P, et al. Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy. Eur J Cardiothorac Surg 2006;29:240-3 https://doi.org/10.1016/j.ejcts.2005.10.045
  12. De Waele M, Serra-Mitjans M, Hendriks J, et al. Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients. Eur J Cardiothorac Surg 2008;33:824-8 https://doi.org/10.1016/j.ejcts.2008.02.007